Search
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Synonyms: (R,R)-3,3'-dithiobis(2-aminopropanoic acid), β,β'-dithiodialanineFlumazenil
go.drugbank.com/drugs/DB01205ApprovedInvestigationalFumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine … receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.
Categories: Heterocyclic Compounds, 2-Ring, Compounds used in a research, industrial, or household settingProducts: ANESED-R 1 MG/10 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADET, ANESED-R 0.5 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 5 ADETCytisine
go.drugbank.com/drugs/DB09028InvestigationalRecent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost. … Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: (1R,5S)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido[1,2a][1,5]diazocin-8-oneBrexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalIt has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. … [A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric
Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin 5-HT1 Receptor AgonistsProducts: REXULTI (BREXPIPRAZOLE) TABLETS 1 MG, REXULTI (BREXPIPRAZOLE) TABLETS 2 MGOlcegepant
go.drugbank.com/drugs/DB04869InvestigationalBoehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.
Categories: Calcitonin Gene-Related Peptide Receptor Antagonists, Calcitonin Gene-Related Peptide, analogs & derivativesInositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnNicotinic acid plays an essential role in many important metabolic processes and has been used as lipid-lowering agent. … It is used in food supplements as a source of niacin (vitamin B3), where hydrolysis of 1 g (1.23 mmol) inositol hexanicotinate yields 0.91 g nicotinic acid and 0.22 g inositol.
Categories: Vitamin B Complex, Heterocyclic Compounds, 1-RingFish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticalFurthermore, a variety of studies regarding additional potential actions of fish oil omega-3-fatty acids EPA and DHA are ongoing. … Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016.
Mixtures: BLACKMORES teen multi for GUYS capsule, BLACKMORES teen multi for GIRLS capsuleCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPropantheline
go.drugbank.com/drugs/DB00782ApprovedA muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.
Categories: Heterocyclic Compounds, 3-RingPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalgrowth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. … exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins.
Categories: Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors, Receptor, Fibroblast Growth Factor, Type 2, antagonists & inhibitorsOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin